Price
No data yet.
Social Signal Score
Revenue
$38.01M+3.43%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David R. Folsom
- Sector
- Real Estate
- Industry
- REIT - Hotel & Motel
- Employees
- 9
- Beta
- 0.68
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -590.85
Financials
Revenue
$38.01M+3.4%Net Income
$-5.53MEBITDA
$4.91M-28.3%Free Cash Flow
$-2.94M-276.4%EPS (diluted)
$-0.27Shares Outstanding (diluted)
20.40M+40.7%Operating Expenses
$1.39MCash & Debt
$9.43MReturn of Capital
$0.00Revenue by Segment (annual)
$176.39MDividend per Share
$0.13Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $181.89M | $1.30M | $-0.34 |
| 2023 | $173.84M | $3.94M | $-0.22 |
| 2022 | $166.08M | $32.54M | $1.40 |
| 2021 | $127.59M | $-26.22M | $-2.15 |
| 2020 | $71.50M | $-49.19M | $-4.05 |
| 2019 | $185.79M | $1.91M | $0.09 |
| 2018 | $178.17M | $109.9K | $0.01 |
| 2017 | $154.27M | $442.5K | $-0.24 |
| 2016 | $152.85M | $926.7K | $-0.01 |
| 2015 | $138.53M | $5.36M | $0.43 |
| 2014 | $122.94M | $2.16M | $-0.06 |
| 2013 | $89.37M | $-2.98M | $-0.29 |
| 2012 | $87.34M | $-4.10M | $-0.41 |
| 2011 | $81.17M | $-4.84M | $-0.50 |
Valuation
SOHOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (3)
- Newsprnewswire.com·5h ago·Neutral
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation …
View source ↗ - Newsbusinesswire.com·5h ago·Neutral
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical d…
View source ↗ - Newsglobenewswire.com·5h ago·Neutral
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presenta…
View source ↗
Earnings
Typical surprise -110.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Mar 12$0.08 vs $0.01beat
- Thu, Nov 13$-0.27 vs $-0.09miss
- Tue, Aug 12$-0.02 vs $0.34miss
- Tue, May 13$0.13 vs $0.16miss
- Thu, Mar 13$-0.16 vs $0.03miss
- Tue, Nov 12$-0.29 vs $0.01miss
Estimates and results for SOHO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SOHO officers and directors.
- Bought
- $24k
- Sold
- $373k
1 trade
9 trades
- Sims Andrewsold
- Sims Andrewsold
- Sims Andrewsold
- Sims Andrewsold
- Folsom David Rbought
- Sims Andrewsold
- Domalski Anthony Esold
- Domalski Anthony Esold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.